六氢呋喃并[2,3-b]呋喃 | 26457-63-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 中文名称: 六氢呋喃并[2,3-b]呋喃
• 英文名称: hexahydrofuro[2,3-b]furan
• 英文别名: 2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan
• CAS: 26457-63-6
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: IHKOXYNAMXNNDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  六氢-呋喃并[2,3-b]呋喃-3-醇 、 六氢呋喃并[2,3-b]呋喃 、 2,3-二氢呋喃 以provide (3R,3aS,6aR) and (3S,3aR,6aS) hexahydro-furo[2,3-b]furan-3-ol的产率得到(3S,3aR,6aS)-六氢呋喃并[2,3-b]呋喃-3-醇
  参考文献：
  名称：

  Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol

  摘要：

  本发明涉及一种制备六氢呋喃[2,3-b]呋喃-3-醇的方法，以及用于该方法的新型中间体。更具体地，本发明涉及一种立体选择性制备六氢呋喃[2,3-b]呋喃-3-醇的方法，以及一种适用于工业放大的方法。

  公开号：

  US07126015B2
• 作为产物：
  描述：

  (+/-)-cis,trans-toluene-4-sulfonic acid (2-methoxytetrahydrofuran-3-yl)methyl ester 在 sodium hydroxide 、 二异丁基氢化铝 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 23.58h， 生成 六氢呋喃并[2,3-b]呋喃
  参考文献：
  名称：

  Total Synthesis of Dihydroclerodin from (R)-(−)-Carvone

  摘要：

  The first total synthesis of the natural enantiomer of the insect-antifeedant dihydroclerodin (1) and lupulin C (40) has been achieved starting from (R)-(-)-carvone (2). In the applied strategy, the hexahydrofuro[2,3-b]furan moiety was introduced in an early stage of the synthesis. The correct configuration at C-9, C-11, C-13, and C-16 was established by application of a remarkably diastereoselective Mukaiyama reaction. The desired configuration at C-10 was obtained by catalytic reduction of the intermediate enone 21. After annulation of the second ring, the structural features at C-4, C-5, and C-6 were introduced. The successful finishing of the synthesis included a Chugaev elimination to give the exocyclic double bond at C-4 that is present in lupulin C. Oxidation of this double bond with m-CPBA afforded dihydroclerodin.

  DOI：

  10.1021/jo991151r

文献信息

• [EN] SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS CYCLIQUES SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
  申请人：XI NING

  公开号：WO2013138210A1

  公开（公告）日：2013-09-19

  The present invention provides novel substituted cyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明提供了新颖的取代环化合物，药用可接受的盐及其制剂，用于调节蛋白酪氨酸激酶活性，并调节细胞活动，如增殖、分化、凋亡、迁移和侵袭。该发明还提供了包括这些化合物的药用可接受的组合物，以及在治疗哺乳动物，特别是人类的增生性疾病中使用这些组合物的方法。
• [EN] HDAC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA HDAC ET SES UTILISATIONS
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009137503A1

  公开（公告）日：2009-11-12

  Inhibitors of histone deacetylase, including compounds having a diazabicyclo[2.2.1]heptan-2-yl moiety are described together with methods for treating various disorders with such compounds.

  抑制组蛋白去乙酰化酶的抑制剂，包括具有二氮杂双环[2.2.1]庚烷-2-基基团的化合物，以及使用这些化合物治疗各种疾病的方法被描述。
• 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20200108075A1

  公开（公告）日：2020-04-09

  3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.

  公式（I）的3-羰基氨基异喹啉化合物及其变体，以及它们作为HPK1（造血激酶1）抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫应答方面是有用的。还描述了抑制HPK1的方法，治疗HPK1依赖性疾病的方法，增强免疫应答的方法，以及制备3-羰基氨基异喹啉化合物的方法。
• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009137499A1

  公开（公告）日：2009-11-12

  Compounds which are histone deacetylase inhibitors and their use in treating various disorders, including Alzheimer's Disease.

  组合物是组蛋白去乙酰化酶抑制剂，用于治疗各种疾病，包括阿尔茨海默病。